DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis.

Author(s): Sydnor TA Jr, Scheld WM, Gwaltney J Jr, Nielsen RW, Huck W, Therasse DG

Affiliation(s): Lilly Research Laboratories, Indianapolis, IN.

Publication date & source: 1992-05, Ear Nose Throat J., 71(5):225-32.

Publication type: Clinical Trial; Randomized Controlled Trial

Loracarbef (LY 163892), a beta-lactam antibiotic (carbacephem), was compared with amoxicillin/clavulanate potassium in a 10-day, single-blind, randomized parallel trial in the treatment of acute bacterial maxillary sinusitis. Based on posttherapy aspirate and culture, there was a 95.2% bacteriologic cure rate in patients receiving loracarbef (400 mg twice daily) and an 86.7% cure rate in patients receiving amoxicillin/clavulanate (500/125 mg three times daily) (p = 0.359). Loracarbef was comparable in efficacy to amoxicillin/clavulanate with a more desirable safety profile.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017